Bladder EpiCheck clinical utility to predict BCG response in non‐muscle‐invasive bladder cancer

Ähnliche Einträge

• Refining BCG ‐failure classifications in non‐muscle‐invasive bladder cancer
  von: Aleksander Ślusarczyk, et al.
  Veröffentlicht: (2026)
• Quality of life and cost‐effectiveness of intravesical gemcitabine/docetaxel vs BCG in BCG ‐naïve non‐muscle‐invasive bladder cancer
  von: Aviral Srivastava, et al.
  Veröffentlicht: (2025)
• Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer
  von: Jacob I. Taylor, et al.
  Veröffentlicht: (2024)
• Biased associations between number of BCG instillations and outcome in non‐muscle‐invasive bladder cancer
  von: Jasper Hof, et al.
  Veröffentlicht: (2025)
• Correction to “Outcomes of BCG vs upfront radical cystectomy for high‐risk non‐muscle‐invasive bladder cancer”
  Veröffentlicht: (2025)